Navigate Fool.com
Will OMED beat
the market?
Community Rating: 3 Stars: Appealing

22.84 -0.52 (-2.23%)

Quote as of

Extended Hours: $22.84 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $23.09
Previous Close $23.36
Daily Range $22.38 - $23.27
52-Week Range $12.07 - $42.34
Market Cap $675.0M
P/E Ratio 4.23
Dividend (Yield) $0.00 (0.0%)
Volume 163,807
Average Daily Volume 191,362
Current FY EPS -$0.86

How do you think OMED
will perform against the market?

Top OMED Bull/Bear Pitches


There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!


There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

Why Oncotheryeon, Inc., OncoMed Pharmaceuticals, Inc., and Array BioPharma Inc. Stocks Jumped Today

Three biotechs climb after a competitor's trial success boosts hope across the HER-2 breast cancer treatment market

Why OncoMed Pharmaceuticals Inc. Shares Surged

OncoMed shares reverse course from Friday's swoon despite the release of mixed news from the company.

This Week in Biotech: Tulipmania Ensues in the Hepatitis C Sector

Five clinical updates that made waves in the biotech sector this week, as well as the surprising buyout that still has Wall Street abuzz.

Down 9%: Is OncoMed a Bad News Buy?

OncoMed shares had a rough day. Time to buy?

Why OncoMed Pharmaceuticals Inc. Shares Collapsed

OncoMed shares dive after it voluntarily halts two early-stage programs. Find out what investors should be closely monitoring going forward.

Friday Sector Laggards: Biotechnology, Drugs

How This 1 Company Is Attempting to Overcome One of Cancer's Greatest Risk Factors

This revolutionary biopharmaceutical company aims to get to the root of treating cancer rather than just scratching at the surface.

The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind

The five biotechs with the largest number of shares sold short as a percentage of float.

What You Ought To Know About Celgene's Deal-Making Magic

Celgene's investment team has made a string of savvy investments in early stage biotech companies.

5 States Where Pancreatic Cancer Prevalence Is the Highest

Pancreatic cancer has the lowest five-year survival rate and is the most prevalent in these five states. Here are the existing and developing therapies you need to have your eyes on.

See More OMED News...




ONCOMED PHARMACEUTICALS INC Website: http://www.oncomed.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks